SV2 regulates neurotransmitter release via multiple mechanisms

American Journal of Physiology - Cell Physiology

Volumn 299, Issue 5, 2010, Pages

  Nowack, Amy ^a   Yao, Jia ^a   Custer, Kenneth L ^b   Bajjalieh, Sandra M ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Exocytosis; Neurotransmission; Synapse

Indexed keywords

MUTANT PROTEIN; NEUROTRANSMITTER; PROTEIN; SYNAPTIC VESICLE PROTEIN 2; SYNAPTOTAGMIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; INTERNALIZATION; KNOCKOUT MOUSE; MOUSE; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN TRANSPORT; SYNAPTIC TRANSMISSION;

ANIMALS; CELLS, CULTURED; EXOCYTOSIS; MEMBRANE GLYCOPROTEINS; MICE; MICE, KNOCKOUT; MUTATION; NERVE TISSUE PROTEINS; NEURONS; NEUROTRANSMITTER AGENTS; PATCH-CLAMP TECHNIQUES; PROTEIN ISOFORMS; RECOMBINANT FUSION PROTEINS; SYNAPSES; SYNAPTIC TRANSMISSION;

MUS; VERTEBRATA;

EID: 78349282226     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00259.2010     Document Type: Article

References (49)

1. Ahlquist RM and Sullivan JM. Overexpression of proteins in neurons using replication-deficient virus. Methods Mol Biol 337: 15-26, 2006.
2. Bajjalieh SM, Franz G, Weimann JM, McConnell SK, Scheller RH. Differential expression of Synaptic Vesicle Protein 2 (SV2) isoforms. J Neurosci 14: 5223-5235, 1994.
3. Bajjalieh SM, Peterson K, Linial M, Scheller RH. Brain contains two forms of synaptic vesicle protein 2. Proc Natl Acad Sci U S A 90: 2150-2154, 1993.
4. Bajjalieh SM, Peterson K, Shinghal R, Scheller RH. SV2, a brain synaptic vesicle protein homologous to bacterial transporters. Science 257: 1271-1273, 1992.
5. Barry SC, Harder B, Brzezinski M, Flint LY, Seppen J, Osborne WR. Lentivirus vectors encoding both central polypurine tract and posttranscriptional regulatory element provide enhanced transduction and transgene expression. Hum Gene Ther 12: 1103-1108, 2001.
6. Bennett B, Matagne A, Michel P, Leonard M, Cornet M, Meeus MA, Toublanc N. Seletracetam (UCB 44212). Neurotherapeutics 4: 117-122, 2007.
7. Brown CR, Hong-Brown LQ, Biwersi J, Verkman AS, Welch WJ. Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones 1: 117-125, 1996.
8. Bushara KO, Malik T, Exconde RE. The effect of levetiracetam on essential tremor. Neurology 64: 1078-1080, 2005.
9. 2+-induced exocytosis. J Neurosci 29: 883-897, 2009.
10. Crowder KM, Gunther JM, Jones TA, Hale BD, Zhang HZ, Peterson MR, Scheller RH, Chavkin C, Bajjalieh SM. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc Natl Acad Sci U S A 96: 115268-115273, 1999.
11. Custer KL, Austin NS, Sullivan JM, Bajjalieh SM. Synaptic vesicle protein 2 enhances release probability at quiescent synapses. J Neurosci 26: 1303-1313, 2006.
12. De Smedt T, Raedt R, Vonck K, Boon P. Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug. CNS Drug Rev 13: 57-78, 2007. (Pubitemid 46705269)
13. Dunteman ED. Levetiracetam as an adjunctive analgesic in neoplastic plexopathies: case series and commentary. J Pain Palliat Care Pharmacother 19: 35-43, 2005.
14. Enggaard TP, Klitgaard NA, Sindrup SH. Specific effect of levetiracetam in experimental human pain models. Eur J Pain 10: 193-198, 2006.
15. Feany MB, Lee S, Edwards RH, Buckley KM. The synaptic vesicle protein SV2 is a novel type of transmembrane transporter. Cell 70: 861-867, 1992.
16. Fernandez-Chacon R, Konigstorfer A, Gerber SH, Garcia J, Matos MF, Stevens CF, Brose N, Rizo J, Rosenmund C, Sudhof TC. Synaptotagmin I functions as a calcium regulator of release probability. Nature 410: 41-49, 2001.
17. Geppert M, Goda Y, Hammer RE, Li C, Rosahl TW, Stevens CF, Sudhof TC. Synaptotagmin I: a major calcium sensor for transmitter release at a central synapse. Cell 79: 717-727, 1994.
18. Gillard M, Chatelain P, Fuks B. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Eur J Pharmacol 536: 102-108, 2006.
19. Gingrich JA, Anderson PH, Tiberi M, Mestikawy S, Jorgensen PN, Fremeau RT, Caron MG. Identification, characterization, and molecular cloning of a novel transporter-like protein localized to the central nervous system. FEBS Lett 312: 115-122, 1992.
20. Hirai T, Heymann JA, Maloney PC, Subramaniam S. Structural model for 12-helix transporters belonging to the major facilitator superfamily. J Bacteriol 185: 1712-1718, 2003.
21. Horn PA, Morris JC, Bukovsky AA, Andrews RG, Naldini L, Kurre P, Kiem HP. Lentivirus-mediated gene transfer into hematopoietic repopulating cells in baboons. Gene Ther 9: 1464-1471, 2002.
22. 2+ transporters but control glucose-evoked granule recruitment. J Cell Sci 118: 5647-5660, 2005.
23. 2+ regulators in neurotransmitter release. Neuron 24: 1003-1016, 1999.
24. Janz R, Hofmann K, Sudhof TC. SVOP, an evolutionarily conserved synaptic vesicle protein, suggests novel transport functions of synaptic vesicles. J Neurosci 15: 9269-9281, 1998.
25. Jessen-Marshall AE, Paul NJ, Brooker RJ. The conserved motif, GXXX(D/E)(R/K)XG[X](R/K)(R/K), in hydrophilic loop 2/3 of the lactose permease. J Biol Chem 270: 16251-16257, 1995.
26. Kasahara T, Kasahara M. Tryptophan 388 in putative transmembrane segment 10 of the rat glucose transporter Glut1 is essential for glucose transport. J Biol Chem 273: 29113-29117, 1998.
27. Kenda BM, Matagne AC, Talaga PE, Pasau PM, Differding E, Lallemand BI, Frycia AM, Moureau FG, Klitgaard HV, Gillard MR, Fuks B, Michel P. Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. J Med Chem 47: 530-549, 2004.
28. Kinrys G, Worthington JJ, Wygant L, Nery F, Reese H, Pollack MH. Levetiracetam as adjunctive therapy for refractory anxiety disorders. J Clin Psychiatry 68: 1010-1013, 2007. (Pubitemid 47340319)
29. Kinrys G, Wygant LE, Pardo TB, Melo M. Levetiracetam for treatment-refractory posttraumatic stress disorder. J Clin Psychiatry 67: 211-214, 2006.
30. Lambeng N, Grossmann M, Chatelain P, Fuks B. Solubilization and immunopurification of rat brain synaptic vesicle protein 2A with maintained binding properties. Neurosci Lett 398: 107-112, 2006.
31. Lazzell DR, Belizaire R, Thakur P, Sherry DM, Janz R. SV2B regulates synaptotagmin 1 by direct interaction. J Biol Chem 279: 52124-52131, 2004.
32. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 101: 9861-9866, 2004.
33. McGavin CL, John V, Musser WS. Levetiracetam as a treatment for tardive dyskinesia: a case report. Neurology 61: 419, 2003.
34. Morgans CW, Kensel-Hammes P, Hurley JB, Burton K, Idzerda R, McKnight GS, Bajjalieh SM. Loss of the synaptic vesicle protein SV2B results in reduced neurotransmission and altered synaptic vesicle protein expression in the retina. PLoS ONE 4: e5230, 2009.
35. Nishiki T, Augustine GJ. Synaptotagmin I synchronizes transmitter release in mouse hippocampal neurons. J Neurosci 24: 6127-6132, 2004.
36. Perry JL, Dembla-Rajpal N, Hall LA, Pritchard JB. A three-dimensional model of human organic anion transporter 1: aromatic amino acids required for substrate transport. J Biol Chem 281: 38071-38079, 2006.
37. Price MJ. Levetiracetam in the treatment of neuropathic pain: three case studies. Clin J Pain 20: 33-36, 2004.
38. Reigada D, Diez-Perez I, Gorostiza P, Verdaguer A, Gomez de Aranda I, Pineda O, Vilarrasa J, Marsal J, Blasi J, Aleu J, Solsona C. Control of neurotransmitter release by an internal gel matrix in synaptic vesicles. Proc Natl Acad Sci USA 100: 3485-3490, 2003. (Pubitemid 36356610)
39. Schivell AE, Mochida S, Kensel-Hammes P, Custer KL, Bajjalieh SM. SV2A and SV2C contain a unique synaptotagmin-binding site. Mol Cell Neurosci 29: 56-64, 2005. (Pubitemid 40603880)
40. Scranton TW, Iwata M, Carlson SS. The SV2 protein of synaptic vesicles is a keratan sulfate proteoglycan. J Neurochem 61: 29-44, 1993. (Pubitemid 23175881)
41. Striano P, Elefante A, Coppola A, Tortora F, Zara F, Minetti C, Striano S. Dramatic response to levetiracetam in post-ischaemic Holmes' tremor. J Neurol Neurosurg Psychiatry 78: 438-439, 2007. (Pubitemid 46591278)
42. Wan QF, Zhou ZY, Thakur P, Vila A, Sherry DM, Janz R, Heidelberger R. SV2 acts via presynaptic calcium to regulate neurotransmitter release. Neuron 66: 884-895, 2010.
43. Wan QF, Zhou ZY, Thakur P, Vila A, Sherry DM, Janz R, Heidelberger R. SV2 acts via presynaptic calcium to regulate neurotransmitter release. Neuron 66: 884-895, 2010.
44. Woods SW, Saksa JR, Baker CB, Cohen SJ, Tek C. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 69: 546-554, 2008. (Pubitemid 351792328)
45. Xu T, Bajjalieh SM. SV2 modulates the size of the readily releasable pool of secretory vesicles. Nat Cell Biol 3: 691-698, 2001. (Pubitemid 32734246)
46. + antiporter of Escherichia coli encoded by transposon Tn10. The role of a conserved sequence motif, GXXXXRXGRR, in a putative cytoplasmic loop between helices 2 and 3. J Biol Chem 267: 19155-19162, 1992.
47. Yao J, Nowack A, Kensel-Hammes P, Gardner RG, Bajjalieh SM. Cotrafficking of SV2 and synaptotagmin at the synapse. J Neurosci 30: 5569-5578, 2010.
48. Zhang W, Connor KM, Davidson JR. Levetiracetam in social phobia: a placebo controlled pilot study. J Psychopharmacol 19: 551-553, 2005. (Pubitemid 41392309)
49. Zivkovic SA, Costa G, Bond G, Abu-Elmagd KM. Treatment of tardive dyskinesia with levetiracetam in a transplant patient. Acta Neurol Scand 117: 351-353, 2008. (Pubitemid 351503327)